What is Daclizumab?
Category: Prescription Drugs
Most popular types: Zinbryta Zenapax
See also: MS Phase 3 Daclizumab Study DECIDE
Daclizumab is an immunosuppresant. It is used to prevent organ rejection in kidney transplants and for the treatment of multiple sclerosis.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 112 | 7 | |
| Prevent organ rejection | 10 | 0 | |
| Participate in clinical trial | 5 | 7 | |
| Stomach transplant | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Why patients stopped taking Daclizumab
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Other | 8 | |
| Did not seem to work | 2 | |
| Doctor's advice | 2 | |
| Course of treatment ended | 1 |
Duration
Stopped taking Daclizumab
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 1 | |
| 1 - 6 months | 2 | |
| 6 months - 1 year | 2 | |
| 2 - 5 years | 5 |
What people switch to and from
Patients started taking Daclizumab after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Teriflunomide (Aubagio) | 2 | |
| Dimethyl fumarate (Tecfidera) | 1 | |
| Natalizumab (Tysabri) | 1 |
Patients stopped taking Daclizumab and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Natalizumab (Tysabri) | 2 | |
| Dimethyl fumarate (Tecfidera) | 1 | |
| Fingolimod (Gilenya) | 1 |
Last updated: